INMUNE BIO INC (INMB) Stock Price, Forecast & Analysis
USA - NASDAQ:INMB - US45782T1051 - Common Stock
INMB Key Statistics, Chart & Performance
The current stock price of INMB is 1.6 USD. In the past month the price decreased by -12.37%. In the past year, price decreased by -73.41%.
INMB Latest News, Press Relases and Analysis
INMB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.05 | 384.72B | ||
| AMGN | AMGEN INC | 14.74 | 173.50B | ||
| GILD | GILEAD SCIENCES INC | 14.41 | 146.45B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.93 | 106.51B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.56 | 69.47B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.25 | 58.04B | ||
| INSM | INSMED INC | N/A | 39.53B | ||
| NTRA | NATERA INC | N/A | 28.78B | ||
| BIIB | BIOGEN INC | 9.25 | 22.70B | ||
| INCY | INCYTE CORP | 16.39 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.21 | 20.54B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.46 | 14.70B |
Related stock screener links
About INMB
Company Profile
INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. The company is headquartered in Boca Raton, Florida and currently employs 22 full-time employees. The company went IPO on 2019-02-04. The firm has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
Company Info
INMUNE BIO INC
225 Ne Mizner Blvd, Suite 640
Boca Raton FLORIDA 92037 US
CEO: Raymond J. Tesi
Employees: 18
Phone: 18589643720
INMUNE BIO INC / INMB FAQ
What does INMUNE BIO INC do?
INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. The company is headquartered in Boca Raton, Florida and currently employs 22 full-time employees. The company went IPO on 2019-02-04. The firm has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
Can you provide the latest stock price for INMUNE BIO INC?
The current stock price of INMB is 1.6 USD. The price decreased by -1.84% in the last trading session.
Does INMUNE BIO INC pay dividends?
INMB does not pay a dividend.
What is the ChartMill technical and fundamental rating of INMB stock?
INMB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is INMUNE BIO INC (INMB) expected to grow?
The Revenue of INMUNE BIO INC (INMB) is expected to grow by 280.95% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for INMB stock?
INMUNE BIO INC (INMB) currently has 18 employees.
What is the market capitalization of INMB stock?
INMUNE BIO INC (INMB) has a market capitalization of 42.54M USD. This makes INMB a Nano Cap stock.
INMB Technical Analysis
INMB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to INMB. While INMB seems to be doing ok healthwise, there are quite some concerns on its profitability.
INMB Financial Highlights
Over the last trailing twelve months INMB reported a non-GAAP Earnings per Share(EPS) of -2.12. The EPS increased by 2.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -147.05% | ||
| ROE | -191.97% | ||
| Debt/Equity | 0 |
INMB Forecast & Estimates
12 analysts have analysed INMB and the average price target is 8.57 USD. This implies a price increase of 435.5% is expected in the next year compared to the current price of 1.6.
For the next year, analysts expect an EPS growth of 24.88% and a revenue growth 280.95% for INMB